INTEGRATED BIOPHARMA INC (INBP) Stock Down 7.46% After Earnings Release

Shares of INTEGRATED BIOPHARMA INC (INBP) experienced a downward movement in the latest trading session, declining 7.46% following the recent corporate disclosures. Market data indicates that the equity opened the session at $0.1823 and reached a high of $0.1823 before touching a low of $0.1823, eventually settling at $0.17 at the close. This price action comes in the wake of the company releasing its financial performance metrics for the quarter and fiscal year ended June 30, 2026.

The recent regulatory reporting details the financial standing of INTEGRATED BIOPHARMA INC for the fourth quarter of fiscal 2026. While explicit per-share earnings and revenue estimates were not formally tracked or posted on major consensus calendars, the company officially reported its comprehensive fiscal year outcomes to the public. These periodic filings provide the official accounting basis for the period, outlining the corporate revenue and net income realizations recorded over the course of the fiscal term.

Examining the broader trading metrics, the equity moved downward from its previous close of $0.1837, shedding $0.0137 per share during the session. The recorded trading range remained narrow at the $0.17 level, reflecting specific liquidity conditions for INTEGRATED BIOPHARMA INC. The 10-day average trading volume stands at approximately 0.02 million shares, providing a baseline context for the day's market activity and investor execution levels.

INTEGRATED BIOPHARMA INC operates within the consumer products sector and is officially classified by the SEC under the pharmaceutical preparations industry grouping. As a participant in this specialized manufacturing field, the company engages in processes related to pharmaceutical and health-related consumer formulations. This operational classification aligns its core business activities with the broader health products manufacturing landscape.

Financial data retrieved from recent SEC submissions outlines the balance sheet and profitability trajectory of INTEGRATED BIOPHARMA INC over multiple fiscal periods. For the fiscal year 2026, the company recorded a net income of $0.8 million, alongside total assets of $24.9 million and total liabilities of $4.6 million. This compares with fiscal year 2025 figures showing a net income of $0.1 million, total assets of $26.2 million, and total liabilities of $7 million. Historical annual revenue milestones include $47 million in fiscal year 2018 and $36.6 million in fiscal year 2013, while the trailing twelve months EPS stands at -0.0533 with a market capitalization of approximately $5.28 million and a 52-week trading range spanning from $0.1375 to $0.4199.

The broader macroeconomic environment during this trading window featured a 10-year to 2-year Treasury yield spread recorded at 0.37, while the CBOE Volatility Index (VIX) registered at 16.07. These macroeconomic indicators outline the prevailing interest rate curve slope and market-wide volatility levels as participants processed corporate earnings reports across various sectors.

In summary, INTEGRATED BIOPHARMA INC (INBP) concluded its latest trading session with a 7.46% decrease in share value, settling at $0.17 following the disclosure of its annual and quarterly financial results. Market participants continue to evaluate the company's asset levels, liability reductions, and net income figures reported in its latest filings alongside prevailing consumer products sector conditions.

FAQ

Why did INBP stock move today?

INTEGRATED BIOPHARMA INC (INBP) stock moved down by 7.46% following the public release of its financial results for the quarter and fiscal year ended June 30, 2026.

What is an earnings release in corporate reporting?

An earnings release is an official public statement issued by a publicly traded company detailing its financial performance, including revenues, net income, and per-share data, for a specific quarter or fiscal year.